-
公开(公告)号：EP0717850B1
公开(公告)日：1997-05-28
申请号：EP94927577.0
申请日：1994-09-07
发明人： LEGAY, François , WENGER, Roland
CPC分类号： G01N33/9493
摘要： A new method of measuring blood levels of immunophilin-binding pharmaceuticals, e.g., cyclosporins, rapamycins, and FK506 compounds, is provided, comprising the novel step of displacing the pharmaceutical from its immunophilin by using a binding competitor, thereby eliminating the need for an extraction step and enhancing the simplicity and accuracy of the assay. Assay kits comprising a binding competitor and a receptor, e.g., a monoclonal antibody, which binds to the pharmaceutical but not significantly to the binding competitor, are also provided, as are new uses of immunophilin-binding compounds as binding competitors in such assays.
摘要翻译： 提供了测量免疫亲和素结合药物例如环孢菌素，雷帕霉素和FK506化合物的血液水平的新方法，其包括通过使用结合竞争剂从其亲免素中取代药物的新步骤，由此消除了对提取 步骤并增强测定的简单性和准确性。 还提供了包含结合竞争剂和受体（例如单克隆抗体）的测定试剂盒，其与药物结合但不显着与结合竞争剂结合，如免疫亲和素结合化合物作为这种测定中的结合竞争剂的新用途。
-
公开(公告)号：EP0717850A1
公开(公告)日：1996-06-26
申请号：EP94927577.0
申请日：1994-09-07
发明人： LEGAY, François , WENGER, Roland
IPC分类号： G01N33
CPC分类号： G01N33/9493
摘要： A new method of measuring blood levels of immunophilin-binding pharmaceuticals, e.g., cyclosporins, rapamycins, and FK506 compounds, is provided, comprising the novel step of displacing the pharmaceutical from its immunophilin by using a binding competitor, thereby eliminating the need for an extraction step and enhancing the simplicity and accuracy of the assay. Assay kits comprising a binding competitor and a receptor, e.g., a monoclonal antibody, which binds to the pharmaceutical but not significantly to the binding competitor, are also provided, as are new uses of immunophilin-binding compounds as binding competitors in such assays.
-
公开(公告)号：EP1682665B1
公开(公告)日：2011-04-27
申请号：EP04797676.6
申请日：2004-11-05
申请人： Novartis AG
发明人： BOLLEKENS, Jacques , CHIBOUT, Salah-Dine , VONDERSCHER, Jacky , LEGAY, François , CORDIER, André , PAPOIAN, Ruben , SCHERER, Andreas
IPC分类号： C12N15/19
CPC分类号： C12N9/0073 , C07K2319/00 , G06Q50/22 , Y02A90/22
摘要： A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants.
-
公开(公告)号：EP1682665A2
公开(公告)日：2006-07-26
申请号：EP04797676.6
申请日：2004-11-05
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BOLLEKENS, Jacques , CHIBOUT, Salah-Dine , VONDERSCHER, Jacky , LEGAY, François , CORDIER, André , PAPOIAN, Ruben , SCHERER, Andreas
IPC分类号： C12N15/19
CPC分类号： C12N9/0073 , C07K2319/00 , G06Q50/22 , Y02A90/22
摘要： A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention is based on a non-preconceived hypothesis and whole organism multi-organ analysis, a compound can be selected for testing in the absence of any biological selection criteria. The resulting organism-wide pattern of the gene expression changes in the transcriptome provides an overview of the activities at the molecular and organism-wide levels. The discovery process of the invention then integrates in vivo profiling and internal and external genomic databases to elucidate the function of unknown proteins, typically within few months. The invention further relates to medical uses of fibroblast growth factor 23 (FGF-23), FGF-23 fragments, FGF-23 C-terminal polypeptides, FGF-23 homologs and/or FGF-23 variants.
-
-
-
搜索结果
4 条记录 (耗时 0.021 秒)
